Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Urokinase
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Sequel Pharma
Deal Size : $35.0 million
Deal Type : Agreement
Microbix Secures Funded Drug Commercialization Agreement
Details : The Agreement provides for Sequel to fund and undertake the necessary work to return Kinlytic (urokinase), a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture, to the U.S. for the clinical indication of venous catheter ...
Brand Name : Kinlytic
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 16, 2023
Lead Product(s) : Urokinase
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Sequel Pharma
Deal Size : $35.0 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
